
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) shares are trading significantly lower Friday after the company paused enrollment in clinical trials with BCX9930 while it investigates elevated serum creatinine levels seen in some patients.
During the investigation, the company will not enroll new patients in the REDEEM-1, REDEEM-2 or RENEW clinical trials. Patients currently enrolled in the trials will continue on the study drug for now.